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Introduction: Since treatment modalities for metastatic recurrent triple-negative breast cancer (mrTNBC) are
limited, a novel treatment approach including immunotherapy is required. We have developed a novel regimen of
personalized peptide vaccination (PPV), in which vaccine antigens are individually selected from a pool of different
peptide candidates based on the pre-existing host immunity. Herein we conducted a phase II study of PPV for
metastatic recurrent breast cancer patients to investigate the feasibility of PPV for mrTNBC.
Methods: Seventy-nine patients with metastatic recurrent breast cancer who had metastases and had failed
standard chemotherapy and/or hormonal therapy were enrolled. They were subgrouped as the mrTNBC group
(n = 18), the luminal/human epidermal growth factor receptor 2 (HER2)-negative group (n = 41) and the
HER2-positive group (n = 18), while the remaining two patients had not been investigated. A maximum of
four human leukocyte antigen (HLA)-matched peptides showing higher peptide-specific immunoglobulin
G (IgG) responses in pre-vaccination plasma were selected from 31 pooled peptide candidates applicable for
the four HLA-IA phenotypes (HLA-A2, -A24, or -A26 types, or HLA-A3 supertypes), and were subcutaneously
administered weekly for 6 weeks and bi-weekly thereafter. Measurement of peptide-specific cytotoxic
T lymphocyte (CTL) and IgG responses along with other laboratory analyses were conducted before and
after vaccination.
Results: No severe adverse events associated with PPV were observed in any of the enrolled patients. Boosting of CTL
and/or IgG responses was observed in most of the patients after vaccination, irrespective of the breast cancer subtypes.
There were three complete response cases (1 mrTNBC and 2 luminal/HER2-negative types) and six partial response cases
(1 mrTNBC and 5 luminal/HER2-negative types). The median progression-free survival time and median overall survival
time of mrTNBC patients were 7.5 and 11.1 months, while those of luminal/HER2-negative patients were 12.2 and
26.5 months, and those of HER2-positive patients were 4.5 and 14.9 months, respectively.
Conclusions: PPV could be feasible for mrTNBC patients because of the safety, immune responses, and possible clinical
benefits.
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Recent advances in chemotherapies, hormonal therapies
and anti-human epidermal growth factor receptor 2
(HER2) therapies have significantly improved the prog-
nosis in metastatic recurrent breast cancer patients.
For example, new chemotherapies using agents such
as nanoparticle albumin-bound paclitaxel (nab-PTX)
[1,2], eribulin mesylate [3,4] and bevacizumab [5-7], new
hormonal therapies such as fluvestrant injection [8,9] or
new anti-HER2 therapies such as those using pertuzumab
[10,11] and trastuzumab emtansine (T-DM1) [12] have
shown significant clinical benefits in metastatic recurrent
breast cancer patients. Despite these novel therapeutic
advances, the treatment modalities for chemotherapy-
resistant triple-negative breast cancer (TNBC) remain
limited, and thus a novel treatment approach including
immunotherapy is required. Nevertheless, no randomized
controlled trials of cancer vaccine have shown promise of
clinical benefit for metastatic recurrent breast cancer
patients, particularly in metastatic recurrent TNBC
(mrTNBC).
We have developed a novel regimen of personalized
peptide vaccination (PPV), in which vaccine antigens are
selected from a pool of 31 different peptide candidates
based on the pre-existing immunoglobulin G (IgG) respon-
ses specific to each peptide before vaccination [13-17].
Most of the peptides employed for PPV, except for those
derived from prostate-related antigens, are known to be
commonly expressed in various types of advanced cancers.
Our previous clinical trials of PPV for patients with ad-
vanced cancers demonstrated the safety and feasibility of
this new approach [13-17]. Here we conducted a phase II
study of PPV for metastatic recurrent breast cancer
to investigate the feasibility of PPV for mrTNBC.
Methods
Patients and methods
Women with a histological diagnosis of metastatic recur-
rent breast cancer were eligible for inclusion in the
present study. All patients were required to have evaluable
recurrent and/or metastatic tumors at the time of entry.
Patients were divided into three different intrinsic sub-
types as follows: luminal (estrogen-receptor-positive)/
HER2-negative type, HER2-positive type (immunohisto-
chemical score 3+ or HER2 gene/chromosome 17 ratio
>2.2 in fluorescence in situ hybridization) and TNBC
(hormone-receptor-negative and HER2-negative). Most
patients had failed standard chemotherapy, but a few
patients who had failed hormonal therapy alone were also
eligible for this study. All patients were required to show
positive IgG responses to at least 2 of the 31 different
vaccine candidate peptides, as reported previously
[13-17]. Other inclusion criteria were as follows: age
between 20 and 80 years; an Eastern Cooperative OncologyGroup (ECOG) performance status of 0 or 1; positive sta-
tus for human leukocyte antigen (HLA)-A2, -A24 or -A26
types, or HLA-A3 supertypes (A3, A11, A31 or A33); life
expectancy of at least 12 weeks; and adequate hematologic,
hepatic and renal function. Exclusion criteria included
pulmonary, cardiac or other systemic diseases; an acute
infection; a history of severe allergic reactions; pregnancy
or nursing; and other inappropriate conditions for enroll-
ment as judged by clinicians. Patients with a lymphocyte
count of <1,000/μL were excluded from the study, since
we previously reported that pre-vaccination lymphocyto-
penia (<1,000 cells/μL) is an unfavorable factor for overall
survival (OS) in cancer patients receiving PPV [17]. The
protocol was approved by the Kurume University Ethical
Committee and registered in the UMIN Clinical Trials
Registry (Registration, number UMIN000001844; Regis-
tration date, 5 April 2009). All patients were given a full
explanation of the protocol and provided their informed
consent before enrollment.
Clinical protocol
This was a phase II study to evaluate the safety and
immunological responses in metastatic recurrent breast
cancer patients under PPV. Thirty-one peptides, whose
safety and immunological effects for other types of cancer
were confirmed in previously conducted clinical studies
[14-17], were employed for vaccination (12 peptides for
HLA-A2, 16 peptides for HLA-A24, 9 peptides for
HLA-A3 supertypes (-A3, -A11, -A31, and -A33) and 4
peptides for HLA-A26) (Additional file 1: Table S1). These
peptides were prepared under the conditions of Good
Manufacturing Practice (GMP) by the PolyPeptide La-
boratories (San Diego, CA, USA) and American Peptide
Company (Vista, CA, USA). Peptides for vaccination of
individual patients were selected in consideration of the
pre-existing host immunity before vaccination, as assessed
by the titers of IgG specific to each of the 31 different
vaccine candidates.
A maximum of four peptides (3 mg/each peptide),
which were selected based on the results of HLA typing
and peptide-specific IgG titers, were subcutaneously ad-
ministered with incomplete Freund’s adjuvant (Montanide
ISA51; Seppic, Paris, France) once a week for six consecu-
tive weeks. After the first cycle of six vaccinations, up to
four antigen peptides, which were re-selected according to
the titers of peptide-specific IgG at the sixth vaccination,
were administered every two weeks. After the second
cycle of six vaccinations, up to four antigen peptides,
which were also re-selected, were administered every four
to eight weeks according to the immune responses after
PPV. These protocols were continued until remarkable
disease progression or disease in remission was shown,
according to the will of the individual patient. During the
PPV, patients were allowed to receive combination therapies
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therapy and radiotherapy. Adverse events were monitored
according to the National Cancer Institute Common
Terminology Criteria for Adverse Events version 3.0
(NCI-CTC Ver.-3.0). Complete blood counts and serum
biochemistry tests were performed after every six vacci-
nations. The clinical responses were determined by the
Response Evaluation Criteria in Solid Tumors (RECIST)
in the vaccinated patients. The RECIST-based clinical
responses were evaluated after nearly 12 vaccinations by
radiological findings of computed tomography (CT) scan
and/or magnetic resonance imaging (MRI), and the best
overall responses during PPV treatment were shown. For
the patients who did not complete the second cycle
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Median times of peptide vaccination 14 (2 to 39) 12 (
aThe Mann-Whitney U test and Fisher-Freeman-Halton exact test were performed to
epidermal growth factor 2; HLA, human leukocyte antigens; mrTNBC, metastatic recwere evaluated, except in the case of patients who had
died before the RECIST-based radiological evaluation.
Measurement of humoral and cellular immune responses
Humoral immune responses specific to each of the 31 pep-
tide candidates were determined by peptide-specific IgG
levels using the Luminex system (Luminex, Austin, TX,
USA), as previously reported [18]. If the titers of peptide-
specific IgG to at least one of the vaccinated peptides in the
post-vaccination plasma were more than two-fold higher
than those in the pre-vaccination plasma, the changes were
considered to be significant, as previously reported [14-17].
Cellular immune responses specific to the vaccinated pep-
tides were evaluated by interferon (INF)-γ ELISPOT using
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2 to 30) 15 (4 to 39) 12 (6 to 22) 0.021
examine P-values for continuous values and categorical values. HER2, human
urrent triple-negative breast cancer; PPV, personalized peptide vaccination.
Table 2 Adverse events during the PPV
Adverse event Grade 1 Grade 2 Grade 3 Grade 4




Edema limbs 2 3
Pain 5




































Anemia 18 9 2 2
Hemoglobin increased 1
Leukocytopenia 22 11 4
Neutropenia 2 6 5 1
Table 2 Adverse events during the PPV (Continued)









AST increased 14 9 2
ALT increased 19 4 2
γ-GTP increased 7 3 2
ALP increased 6 1 1
Hyperbilirubinemia 3 1 1
Creatinine increased 10 3 1
Cholesterol high 4
Hypoalbuminemia 46 7
INR increased 1 1 1
APTT increased 1
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; APTT, activated partial thromboplastin time; γ-GTP,
gamma-glutamyl transpeptidase; INR, international normalized ratio; PPV,
personalized peptide vaccination.
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specific to CEF peptides (MABTECH, Cincinnati, OH,
USA), a mixture of virus-derived cytotoxic T lymphocyte
(CTL) epitopes, were also examined.
Statistical analyses
The Mann-Whitney U test and Fisher-Freeman-Halton
exact test were used to examine statistical differences for
continuous values and categorical values, respectively.
P-values less than 0.05 were considered to be statistically
significant. Progression-free survival (PFS) or OS was cal-
culated from the date of the first vaccination until the date
of disease progression or death, respectively, or the last
date when the patient was known to be alive. The survival
analysis was performed using the Kaplan-Meier method,
and a comparison of the survival curves was performed
with the log-rank test. Statistical tests were performed
using JMP version 10 (SAS Institute Inc., Cary, NC, USA)
and StatXact version 8 (Cytel Inc., Cambridge, MA, USA).
Results
Patient characteristics
Between January 2009 and April 2013, 79 metastatic
recurrent breast cancer patients were enrolled in this
study. The patient characteristics are shown in Table 1
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subtypes. Among the 79 patients, 77 patients had been
investigated to determine their intrinsic subtype before
vaccination, while the remaining 2 patients had not. The
HER2-positive group was associated with older median
age (P = 0.019), restricted performance status (P = 0.046),
higher positivity of HLA-A24 or -A2 (P = 0.039 or
P = 0.015), higher frequency of visceral or brain metasta-
sis (P = 0.009 or P = 0.002) and longer duration of pre-
vious chemotherapies (P <0.0001). Although the mrTNBC
group had a shorter duration of previous chemotherapies
(P <0.0001), most of the mrTNBC patients had received
previous standard chemotherapy (anthracycline, P = 0.003;
taxane, P = 0.0006).
Combined therapies and adverse events
The median number of peptide vaccinations was 14,
with a range from 2 to 39 vaccinations (Table 1). Table 2
shows all adverse events during the PPV. As the
vaccination-related adverse events, all patients showed
grade 1 or 2 dermatological reactions to PPV at the in-
jection sites, but no patients showed severe adverse
events (grade 3 or more). Forty-one patients (52.0%)
showed grade 3 or 4 adverse events strongly associatedFigure 1 Clinical responses to PPV. a, b) Computed tomography finding
12th vaccination. A 63-year-old woman with a recurrent lung mass underwen
for three weeks followed by one week intermission). At four months after the
c, d) Computed tomography findings of a SD case with mrTNBC (case 18 in T
with a recurrent lung mass underwent eight vaccinations in combination wit
followed by one week intermission). At three months after the first vaccinatio
metastatic recurrent triple negative breast cancer; PPV, personalized peptide vwith combined chemotherapies and disease progression
(Table 2).
During the PPV, 51 patients (64.6%; 32 cases with
infusion chemotherapy and 19 cases with oral chemo-
therapy) received combined chemotherapies, while 23
patients (29.1%) and 11 patients (13.9%) received hor-
monal therapies and anti-HER2 therapies, respectively
(Table 1). The mrTNBC patients received combined
infusion chemotherapy more frequently than other
breast cancer subtypes (P = 0.038). The most commonly
used chemotherapy drug was capecitabine (fifteen cases;
19.0%), followed by gemcitabine (eight cases; 10.1%), eri-
bulin mesylate (six cases; 7.6%), FEC (5-fluorouracil,
epirubicin and cyclophosphamide), nab-PTX or vinorel-
bine (four cases each; 5.1%), paclitaxel (three cases;
3.8%), bevacizumab, irinotecan or S-1 (two cases each;
2.5%), and docetaxel, oral cyclophosphamide or tegafur
(one case each; 1.3%). Eleven patients (13.9%) received
combined anti-HER2 therapies including trastuzumab
(six cases; 7.6%) and lapatinib (five cases; 6.3%); com-
bined anti-HER2 therapy was the most used treatment
for the HER2-positive group (P <0.0001). In addition, 23
patients (29.1%) received combined hormonal therapies
using agents, such as aromatase inhibitor (16 cases;
20.3%), high-dose toremifene (5 cases; 6.3%) ands of a PR case with mrTNBC (case 2 in Table S2) before and after the
t 12 vaccinations in combination with gemcitabine (1,000 mg/m2/week
first vaccination, the lung mass was remarkably reduced in size (arrow).
able S2) before and after the eighth vaccination. A 34-year-old woman
h two cycles of eribulin mesylate (1.4 mg/m2/week for two weeks
n, the lung mass was slightly decreased in size (arrow). mrTNBC,
accination; PR, partial response; SD, stable disease.
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was the most used treatment for the luminal/HER2-
negative group (P = 0.046).
Immune responses to the vaccinated peptides
Both humoral and cellular immune responses specific to
the vaccinated peptides were analyzed in blood samples
before and after vaccination. Plasma samples were collec-
ted from 79, 75, or 53 patients before vaccination, at the
6th vaccination, or at the 12th vaccination, respectively.
For the monitoring of humoral immune responses,
peptide-specific IgGs reactive to each of the 31 different
peptides, including both vaccinated and non-vaccinated
peptides, were measured by bead-based multiplex assay.
The numbers of peptides employed for the first cycle of
vaccinations were 2, 3, or 4 in 8, 6, or 63 patients, respect-
ively (Additional file 2: Table S2, Additional file 3: Table S3,
and Additional file 4: Table S4). Augmentation of IgG
responses specific to at least one of the vaccinated peptides
after 6 or 12 vaccinations was observed in 53/75 (70.7%)
patients or 50/53 (94.3%) patients, respectively. Peptide-
specific IgG responses after 6 or 12 vaccinations were aug-
mented in 7/15 (46.7%) patients or 9/10 (90%) patients
with mrTNBC (Additional file 2: Table S2). Such augmen-
tation was seen in 28/40 (70.0%) patients or 29/31 (93.5%)Figure 2 Expressions of TAAs and pathological responses to PPV. Afte
eribulin mesylate (1.4 mg/m2/week for two weeks followed by one week in
in Table S2) was resected at three months after the first vaccination. The TA
examined by immunohistochemistry. a, b) Among the four TAAs, that is, SA
a) EGF-R (X200); b) SART2 (X200). c, d) Peritumoral infiltration of T lymphoc
d) CD8+ T lymphocytes (X200). EGF-R, epidermal growth factor receptor; L
recurrent triple negative breast cancer; PPV, personalized peptide vaccinatio
antigen recognized by T-cells 2; SD, stable disease; TAA, tumor associated apatients in the luminal/HER2-negative group (Additional
file 3: Table S3) and in 16/18 (88.9%) patients or 11/11
(100%) patients of the HER2-positive group (Additional
file 4: Table S4), respectively.
Cellular immune responses to vaccinated peptides were
assessed by IFN-γ ELISPOT assay. Antigen-specific CTL
responses were detectable in 17/66 (25.8%) patients before
vaccination (Additional file 2: Table S2, Additional file 3:
Table S3 and Additional file 4: Table S4). In contrast,
augmentation of the CTL responses specific to at least
one of the vaccinated peptides after six vaccinations was
observed in 34/63 patients (54.0%). Peptide-specific CTL
responses after six vaccinations were augmented in 7/14
(50.0%) patients with mrTNBC (Additional file 2: Table S2),
while such augmentation was seen in 18/31 (58.1%)
patients and 7/16 (43.8%) patients in the luminal/HER2-
negative group (Additional file 3: Table S3) and HER2-
positive group (Additional file 4: Table S4), respectively.
We also tested CTL responses to CEF peptides, a mix-
ture of virus-derived CTL epitopes, as a control. CTL
responses to CEF peptides were observed in 27/62
(43.5%) patients before vaccination and 15/58 (25.9%)
patients after six vaccinations (Additional file 2: Table
S2, Additional file 3: Table S3 and Additional file 4:
Table S4).r completion of eight vaccinations in combination with two cycles of
termission), the lung metastasis of a SD case with mrTNBC (case 18
A expression and T cell infiltration in the resected lung tissue were
RT2, PSA, EGF-R and LCK, two TAAs were expressed in the lung tumor.
ytes was confirmed in the lung tumor. c) CD4+ T lymphocytes (X200);
CK, lymphocyte specific protein tyrosine kinase; mrTNBC, metastatic
n; PSA, prostate specific antigen; SART2, squamous cell carcinoma
ntigens.
Figure 3 Survival curves among the three intrinsic subtypes.
a) The median progression-free survival time of mrTNBC patients
was 7.5 months, while that of luminal/HER2-negative patients was
12.2 months, and that of HER2-positive patients was 4.5 months.
b) The median overall survival time of mrTNBC patients was
11.1 months, while that of luminal/HER2-negative patients was
26.5 months, and that of HER2-positive patients was 14.9 months.
HER2, human epidermal growth factor receptor 2; mrTNBC, metastatic
recurrent triple negative breast cancer.
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creased CTL and IgG responses to the vaccinated pep-
tides, 23/63 (36.5%) patients showed either increased CTL
or IgG responses, and the remaining 10 (15.9%) patients
showed neither CTL nor IgG boosting. In patients treated
with PPV alone (n = 27), IgG responses were more fre-
quently increased than those in patients treated with com-
bined chemotherapies (n = 47) (P = 0.002), although there
was no significant difference in the increase in CTL
responses (P = 1.000).
Clinical responses to PPV
The RECIST-based clinical responses were evaluated in 64
patients by radiological findings. There were 3 complete
response (CR), 6 partial response (PR), 27 stable disease
(SD) and 28 progressive disease (PD). The overall response
rate of PPV was 14%, including three CR and six PR cases.
Among the responsive patients, combined chemotherapy
was used in eight cases and hormonal therapy in one case.
The intrinsic subtypes showed one mrTNBC and two
luminal/HER2-negative types in the CR cases and one
mrTNBC and five luminal/HER2-negative types in the
PR cases. Computed tomography findings of each of
the mrTNBC cases showing PR or SD are shown in
Figure 1. The PR case (case 2 in Additional file 2: Table S2)
was a 63-year-old woman with a recurrent lung mass
treated with a combination of gemcitabine and PPV. At
four months after the first vaccination, the lung mass was
remarkably reduced in size (Figure 1a and Figure 1b). She
survived 32 months after the first vaccination and died due
to disease progression. The SD case (case 18 in Additional
file 2: Table S2) was a 34-year-old woman with a recurrent
lung mass treated with a combination of eribulin mesylate
and PPV. At three months after the first vaccination, the
lung mass was slightly decreased in size (Figure 1c and
Figure 1d). She was subsequently treated by radical resec-
tion of the lung mass and pathological evaluation. The lung
mass was metastatic TNBC with a high Ki-67 labeling
index (42.0%). It expressed epidermal growth factor recep-
tor (EGF-R) and squamous cell carcinoma antigen recog-
nized by T-cells 2 (SART2) antigens which were vaccinated
antigens (Figure 2a and Figure 2b), and peritumoral infil-
tration of T lymphocytes was confirmed (Figure 2c and
Figure 2d). She is still alive at 13 months following the first
vaccination.
Survival analyses by intrinsic subtypes
Figure 3 shows survival curves for the three intrinsic sub-
types. The median progression-free survival time (MPFST)
and median overall survival time (MST) of mrTNBC pa-
tients were 7.5 and 11.1 months, while those of luminal/
HER2-negative patients were 12.2 and 26.5 months, and
those of HER2-positive patients were 4.5 and 14.9 months,
respectively. For each intrinsic subtype, the survival curveswere compared for patients treated with PPV plus concur-
rent chemotherapies and those treated with PPV alone
(Figure 4). There was no significant survival advantage of
concurrent chemotherapies in each intrinsic subtype, com-
pared with treatment with PPV alone (mrTNBC: PFS and
OS, P = 0.467 and P = 0.347, respectively; luminal/HER2-
negative type: PFS and OS, P = 0.220 and P = 0.850, re-
spectively; and HER2-positive type: PFS and OS, P = 0.296
and P = 0.957, respectively).
Survival analyses along with analyses of the immune re-
sponses to PPV were also conducted in the three subtypes.
Figure 5 shows the survival curves for patients with or
without increased IgG responses after PPV in each intrin-
sic subtype. IgG boosting was a significant prognostic
factor for OS and PFS in HER2-positive patients, whereas
there was no significant difference between increased IgG
responses and these prognoses in mrTNBC and luminal/
HER2-negative patients (mrTNBC: PFS and OS, P = 0.274
and P = 0.152, respectively; luminal/HER2-negative type:
PFS and OS, P = 0.732 and P = 0.571, respectively; HER2-
positive type: PFS and OS, P = 0.0001 and P = 0.001, re-
spectively). Figure 6 shows the survival curves for patients
Figure 4 Survival curves for patients treated with PPV with or without combination chemotherapies. a-f) There was no significant survival
advantage of combined chemotherapies (CC) in each intrinsic subtype, compared with the treatment by PPV alone. a) b) mrTNBC: PFS and OS,
P = 0.467 and P = 0.347, respectively. c,d) luminal/HER2-negative type: PFS and OS, P = 0.220 and P = 0.850, respectively. e,f) HER2-positive type:
PFS and OS, P = 0.296 and P = 0.957, respectively. HER2, human epidermal growth factor receptor 2; mrTNBC, metastatic recurrent triple negative
breast cancer; OS, overall survival; PFS, progression-free survival; PPV, personalized peptide vaccination.
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each intrinsic subtype. CTL boosting was suggested to be
a potential prognostic factor for OS but not for PFS in
mrTNBC patients, whereas there was no significant
difference between CTL boosting and these prognoses
in luminal/HER2-negative and HER2-positive patients
(mrTNBC: PFS and OS, P = 0.345 and P = 0.053, respect-
ively; luminal/HER2-negative type: PFS and OS, P = 0.272
and P = 0.740, respectively; HER2-positive type: PFS and
OS, P = 0.714 and P = 0.758, respectively).
Discussion
Since treatment outcomes in mrTNBC patients remain
poor [19-21], a novel treatment modality including im-
munotherapy is required. Several tumor associated anti-
gens (TAAs), such as cancer testis antigens, EGF-R,
aldehyde dehydrogenase 1 (ALDH1) and enhancer of zeste
homolog 2 (EZH2), are frequently expressed in TNBC,
particularly in basal-like subtypes [22-24]. Despite these
potential molecular targets for immunotherapy in TNBC,
no randomized controlled trials of cancer vaccine have
shown promise of clinical benefit to date. We have devel-
oped a novel regimen of PPV, in which vaccine antigensare selected and administered from a pool of 31 different
peptide candidates based on the pre-existing IgG re-
sponses specific to peptides before vaccination [13-17]. In
previous studies, PPV was feasible for the vast majority of
cancer patients with different HLA-types [13-17]. Based
on these results in cancer patients, we conducted a phase
II study of PPV for metastatic recurrent breast cancer
patients to investigate the feasibility of PPV for mrTNBC.
There were no severe adverse events associated with PPV,
and most of the mrTNBC patients showed augmented
immune responses to PPV.
The current study suggested the feasibility of PPV for
mrTNBC patients who had failed standard chemother-
apy, since the MPFST and MST of mrTNBC patients
were 7.5 and 11.1 months from the first vaccination,
respectively. In previously reported studies, the MPFST
of mrTNBC patients treated by various chemotherapy
and/or targeted therapy regimens was between 2.5 and
6.5 months [7,25-28]. Therefore, the MPFST of 7.5 months
in mrTNBC patients treated by PPV in the current study
seemed to be promising. Regarding OS in TNBC patients,
Dent et al. demonstrated that the MST from recur-
rence to death was nine months, although the details
Figure 5 Survival curves for patients with or without increased IgG responses after PPV. a-f) IgG boosting was a significant prognostic
factor for OS and PFS in HER2-positive patients, whereas there was no significant difference between increased IgG responses and these prognoses in
mrTNBC and luminal/HER2-negative patients. a, b) mrTNBC: PFS and OS, P = 0.274 and P = 0.152, respectively. c, d) luminal/HER2-negative type: PFS
and OS, P = 0.732 and P = 0.571, respectively. e, f) HER2-positive type: PFS and OS, P = 0.0001 and P = 0.001, respectively. HER2, human epidermal
growth factor receptor 2; IgG, immunoglobulin G; mrTNBC, metastatic recurrent triple negative breast cancer; OS, overall survival; PFS, progression-free
survival; PPV, personalized peptide vaccination.
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recently conducted studies showed that the MST of
mrTNBC patients treated by various chemotherapy and/
or targeted therapy regimens was between 7.7 and
17.9 months [26-28]. Although almost all patients in
these previous studies were enrolled as a first-line and/or
second-line treatment [26-28], most patients in the
current study were enrolled as a third or more line treat-
ment. In addition, considering that the median duration of
previous chemotherapies in the mrTNBC patients in the
current study was 9 months, the MST of 11.1 months in
mrTNBC patients treated by PPV seems to be encour-
aging. As a next step, to clarify the clinical benefit of PPV
in mrTNBC, we need to conduct a randomized controlled
study, in which patients are treated with standard of care
(SOC) alone or with PPV plus SOC.
Although the results of immune responses were not
significantly different by intrinsic subtypes, a high popu-
lation of HER2-positive patients showed IgG responses
at the sixth vaccination. Since all of the HER2-positive
patients had been treated with trastuzumab, antigen-
dependent cellular cytotoxicity might have affected theirhumoral immunities [29]. Notably, IgG boosting was a
significant prognostic factor for OS and PFS in HER2-
positive patients, although the number of patients was too
small to confirm this. Combined chemotherapies also
might affect the status of IgG responses, but no survival
advantages of combined chemotherapies were shown in
our metastatic recurrent breast cancer patients.
The clinical response rate in the present series was
14.0%, including three CR and six PR cases. Among
these responsive patients, combined chemotherapy was
used in eight cases and hormonal therapy in one case.
The intrinsic subtype of these patients was luminal/
HER2-negative type in seven cases and mrTNBC in two
cases. Notably, the number of previous chemotherapy
regimens was one regimen in two patients and two regi-
mens in seven patients. In our study, more than four
regimens of previous chemotherapy were significantly
correlated with poor prognosis (data not shown). From
these results, we would recommend PPV within three
regimens of previous chemotherapy for metastatic recur-
rent breast cancer patients. A greater number of previous
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Figure 6 Survival curves for patients with or without increased CTL responses after PPV. a-f) CTL boosting was suggested to be a
potential prognostic factor for OS but not for PFS in mrTNBC patients, whereas there was no significant difference between CTL boosting and
these prognoses in luminal/HER2-negative and HER2-positive patients. a, b) mrTNBC: PFS and OS, P = 0.345 and P = 0.053, respectively. c, d)
luminal/HER2-negative type: PFS and OS, P = 0.272 and P = 0.740, respectively. e, f) HER2-positive type: PFS and OS, P = 0.714 and P = 0.758,
respectively. CTL, cytotoxic T lymphocytes; HER2, human epidermal growth factor receptor 2; mrTNBC, metastatic recurrent triple negative breast
cancer; OS, overall survival; PFS, progression-free survival; PPV, personalized peptide vaccination.
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patients. Because of the significant clinical benefit and
conventional usage of trastuzumab, the duration of previ-
ous chemotherapy was significantly prolonged in HER2-
positive patients. The status of tumor molecular biology
could change and be complicated by this long-term
chemotherapy, eventually leading to a poor prognosis. For
HER2-positive patients, the induction of PPV should be
earlier than that in our HER2-positive patients. Since
combined chemotherapies increase the number of severe
adverse events in metastatic breast cancer patients, treat-
ment with PPV alone should be performed to maintain
their quality of life.
We had an opportunity to confirm the peritumoral in-
filtration of lymphocytes in the lung metastasis of
mrTNBC. Two of the four vaccinated peptide antigens
(EGF-R and squamous cell carcinoma antigen recognized
by T-cells 2 (SART2)) were expressed in the lung tumor,
and CTL responses to the SART2-93 antigen were signifi-
cantly increased in this case (case 18 in Additional file 2:
Table S2). Although IgG responses to the two peptide
antigens were not significantly increased, PPV could en-
hance the anti-tumor immunity and efficacy of combinedchemotherapy in this case. We have investigated the ex-
pressions of 15 TAAs in primary and recurrent breast can-
cer tissues by immunohistochemistry (RT, unpublished
data). We found that 10 of 15 TAAs were expressed in
both primary and recurrent breast cancer tissues, except
for lymphocyte specific protein tyrosine kinase (LCK),
prostate specific antigen (PSA), prostate specific mem-
brane antigen (PSMA), prostatic acid phosphatase (PAP)
and multidrug resistance-associated protein 3 (MRP3).
However, four of these five TAAs, including LCK, PSA,
PAP and MRP3, were reported to be expressed in breast
cancer tissues, although the frequency of expression was
lower than that of other TAAs [30-34]. Therefore, 14 of
the 15 TAAs could be potential molecular targets for
immunotherapy in breast cancer patients.
Conclusions
In conclusion, PPV could be feasible for mrTNBC
patients because of the safety, immune responses and
possible clinical benefits. For mrTNBC patients, we are
planning a randomized controlled study, in which pa-
tients are treated with SOC alone or with PPV plus SOC
to further clarify the clinical benefit of PPV.
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